Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-102.50K) by net assets ($491.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Drugs Made In America Acquisition II Cor to measure how much of total assets are equity-financed.
Drugs Made In America Acquisition II Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Drugs Made In America Acquisition II Cor earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ca Toulouse 31 CCI
PA:CAT31
|
0.046x |
|
NatWest Group PLC
LSE:NWG
|
0.011x |
|
Destiny Tech100 Inc.
NYSE:DXYZ
|
-0.023x |
|
Mama's Creations Inc.
NASDAQ:MAMA
|
0.054x |
|
Skipper Limited
NSE:SKIPPER
|
0.092x |
|
Tiptree Inc
NASDAQ:TIPT
|
-0.024x |
|
Jiangsu Zhenjiang New Energy Equipment Co Ltd Class A
SHG:603507
|
-0.026x |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. For the full company profile with market capitalisation and key ratios, see Drugs Made In America Acquisition II Cor (DMII) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $487.16 Million | $-1.02 Million | -0.002x | -100.13% |
| 2024-12-31 | $-116.72K | $-194.30K | 1.665x | -- |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp… Read more